Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

Norikazu Masuda,1 Yucherng Chen,2 Tsutomu Kawaguchi,3 Koji Dozono,4 Masakazu Toi5 1Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2Safety Science, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan; 3Medicines Development Unit, El...

Full description

Bibliographic Details
Main Authors: Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M
Format: Article
Language:English
Published: Dove Medical Press 2022-03-01
Series:Cancer Management and Research
Subjects:
abemaciclib
breast cancer
cyclin-dependent kinase 4/6
fulvestrant
nonsteroidal aromatase inhibitor
Online Access:https://www.dovepress.com/safety-in-japanese-advanced-breast-cancer-patients-who-received-abemac-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/safety-in-japanese-advanced-breast-cancer-patients-who-received-abemac-peer-reviewed-fulltext-article-CMAR

Similar Items